Table 5.
Fold Change Data Analysis of Tested Circulating MiR-106a in the Serum of Cancer Patients
| GAPDH Ct | MiR-106a Ct | Δ Ct | ΔΔ Ct | FC | |
|---|---|---|---|---|---|
| Compared to the healthy control group | |||||
| Control | 27.29 | 27.82 | 0.53 | 0 | 1.00 |
| Patients | 25.78 | 24.57 | -1.20 | -1.73 | 3.63 |
| Pathological grade | |||||
| Grade I | 23.30 | 22.32 | -0.99 | -1.51 | 2.85 |
| Grade II | 26.04 | 24.79 | -1.24 | -1.77 | 3.80 |
| Grade III | 26.03 | 24.90 | -1.13 | -1.65 | 3.34 |
| Grade IV | 23.86 | 22.45 | -1.41 | -1.94 | 3.83 |
| Clinical Stage | |||||
| Stage I | 24.76 | 23.52 | -1.25 | -1.77 | 3.73 |
| Stage II | 25.93 | 24.69 | -1.24 | -1.77 | 3.73 |
| Stage III | 25.77 | 24.70 | -1.08 | -1.60 | 3.32 |
| Pathological type | |||||
| IDC | 25.89 | 24.62 | -1.27 | -1.80 | 3.80 |
| ILC | 25.87 | 24.67 | -1.21 | -1.73 | 3.47 |
| ICC | 23.30 | 22.32 | 0.99 | -1.51 | 2.85 |
| Auxiliary lymph node | |||||
| Positive | 25.98 | 24.78 | 1.20 | -1.73 | 3.66 |
| Negative | 24.75 | 23.59 | -1.20 | -1.73 | 3.51 |
| Tumor size | |||||
| T1 < 2 | 25.38 | 24.12 | -1.26 | -1.79 | 3.80 |
| T2 2–5 | 25.92 | 24.76 | -1.16 | -1.69 | 3.54 |
| T3 > 5 | 25.40 | 23.98 | -1.43 | -1.95 | 4.05 |
| Estrogen receptor | |||||
| Negative | 25.82 | 24.50 | -1.32 | -1.84 | 3.95 |
| Positive | 25.72 | 24.68 | -1.04 | -1.57 | 3.16 |
| Progesterone receptor | |||||
| Negative | 25.67 | 24.38 | -1.30 | -1.82 | 3.87 |
| Positive | 25.99 | 24.96 | -1.02 | -1.55 | 3.15 |
| HER-2 | |||||
| Positive | 25.42 | 24.16 | -1.26 | -1.78 | 3.83 |
| Negative | 25.90 | 24.72 | -1.19 | -1.71 | 3.56 |
| Family History | |||||
| Yes | 26.40 | 24.99 | -1.41 | -1.94 | 4.16 |
| No | 25.59 | 24.44 | -1.14 | -1.67 | 3.47 |